Latest Therapeutics News

Page 16 of 90
Recce Pharmaceuticals has expanded its intellectual property footprint with a key patent granted in Vietnam for its RECCE® anti-infective drugs, reinforcing its presence in a critical Southeast Asian market grappling with high antibiotic resistance.
Victor Sage
Victor Sage
14 July 2026
Neurotech International has secured FDA clearance for its Investigational New Drug application for NTI164, enabling clinical development in the US and advancing its global registration and commercialisation plans.
Ada Torres
Ada Torres
14 July 2026
Biotron Limited has met the first milestone in its Sedarex acquisition by securing pivotal regulatory feedback from the European Medicines Agency, charting a clearer path for its next-generation anaesthetic SedRx.
Ada Torres
Ada Torres
13 July 2026
INOVIQ Limited hit a roadblock in expanding clinical validation of its EXO-OC™ ovarian cancer test due to unsuitable biobank samples, yet improved its diagnostic algorithm and progressed its CAR-exosome therapeutic program, maintaining a solid cash position of A$9.35 million.
Ada Torres
Ada Torres
13 July 2026
OncoSil Medical has completed key manufacturing validation cycles with Cyclotek, paving the way for scalable Australian production of its OncoSil™ device. With a $2.1 million capital investment, the company aims to boost margins and supply chain control ahead of commercial launch in late 2026.
Ada Torres
Ada Torres
13 July 2026
CLINUVEL Pharmaceuticals secures Canadian marketing approval for SCENESSE®, expanding access to the only approved systemic photoprotective treatment for erythropoietic protoporphyria (EPP).
Victor Sage
Victor Sage
13 July 2026
Patrys has assigned its deoxymab intellectual property to Yale University in a deal granting it half of all future commercialisation revenue, reducing capital needs while keeping long-term upside.
Ada Torres
Ada Torres
13 July 2026
Island Pharmaceuticals is progressing its broad-spectrum antiviral Galidesivir amid a severe Ebola outbreak, securing government approvals in Uganda and outlining a dual clinical and regulatory development pathway targeting multiple deadly filoviruses.
Ada Torres
Ada Torres
8 July 2026
Alterity Therapeutics has secured official FDA confirmation that a single pivotal Phase 3 trial, backed by prior Phase 2 data, can support approval of ATH434 for Multiple System Atrophy. Trial initiation remains on track for late 2026.
Ada Torres
Ada Torres
7 July 2026
Noxopharm has taken a key regulatory step by requesting a pre-IND meeting with the US FDA for its autoimmune drug candidate SOF-SKN, aiming to smooth the path for clinical development and boost its commercial appeal.
Ada Torres
Ada Torres
7 July 2026
PainChek announces the immediate departure of CEO Philip Daffas, with COO Andy Hoggan stepping in as interim leader amid a strategic pivot to boost US market growth following FDA clearance.
Ada Torres
Ada Torres
6 July 2026
Nexalis Therapeutics has ended funding negotiations with Point8 Capital after failing to secure a formal agreement, while successfully completing its IRX-616a Phase 1 trial with no serious adverse events. The company is reassessing clinical priorities amid funding uncertainty.
Ada Torres
Ada Torres
6 July 2026

Browse the archive

Full archive